Literature DB >> 17641675

Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41.

J Espallergues1, P Lapalud, A Christopoulos, V A Avlani, P M Sexton, A Vamvakides, T Maurice.   

Abstract

BACKGROUND AND
PURPOSE: Tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanmethanamine hydrochloride (ANAVEX1-41) is a potent muscarinic and sigma(1) (sigma (1)) receptor ligand. The sigma (1) receptor modulates glutamatergic and cholinergic responses in the forebrain and selective agonists are potent anti-amnesic and antidepressant DRUGS. WE HAVE HERE ANALYSED THE SIGMA (1) COMPONENT IN THE BEHAVIOURAL EFFECTS OF ANAVEX1-41. EXPERIMENTAL APPROACH: Binding of ANAVEX1-41 to muscarinic and sigma (1) receptors were measured using cell membranes. Behavioural effects of ANAVEX1-41 were tested in mice using memory (spontaneous alternation, passive avoidance, water-maze) and antidepressant-like activity (forced swimming) procedures. KEY
RESULTS: In vitro, ANAVEX1-41 was a potent muscarinic (M(1)>M(3), M(4)>M(2) with K(i) ranging from 18 to 114 nM) and selective sigma (1) ligand (sigma (1), K(i)=44 nM; sigma (2), K(i)=4 microM). In mice, ANAVEX1-41 failed to affect learning when injected alone (0.03-1 mg kg(-1)), but attenuated scopolamine-induced amnesia with a bell-shaped dose response (maximum at 0.1 mg kg(-1)). The sigma (1) antagonist BD1047 blocked the anti-amnesic effect of ANAVEX1-41 on both short- and long-term memories. Pretreatment with a sigma (1) receptor-directed antisense oligodeoxynucleotide prevented effects of ANAVEX1-41 only in the passive avoidance procedure, measuring long-term memory. ANAVEX1-41 reduced behavioural despair at 30 and 60 mg kg(-1), without involving the sigma (1) receptor, as it was not blocked by BD1047 or the antisense oligodeoxynucleotide. CONCLUSIONS AND IMPLICATIONS: ANAVEX1-41 is a potent anti-amnesic drug, acting through muscarinic and sigma (1) receptors. The latter component may be involved in the enhancing effects of the drug on long-term memory processes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641675      PMCID: PMC1978257          DOI: 10.1038/sj.bjp.0707386

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

Review 1.  Nonsynaptic communication in the central nervous system.

Authors:  E Sylvester Vizi; Janos P Kiss; Balazs Lendvai
Journal:  Neurochem Int       Date:  2004-09       Impact factor: 3.921

2.  Reduction of the scopolamine-induced impairment of passive-avoidance performance by sigma receptor agonist in mice.

Authors:  T Senda; K Matsuno; T Kobayashi; S Mita
Journal:  Physiol Behav       Date:  1997-02

3.  Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats.

Authors:  T Senda; K Matsuno; K Okamoto; T Kobayashi; K Nakata; S Mita
Journal:  Eur J Pharmacol       Date:  1996-11-07       Impact factor: 4.432

4.  Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test.

Authors:  K Matsuno; T Kobayashi; M K Tanaka; S Mita
Journal:  Eur J Pharmacol       Date:  1996-10-03       Impact factor: 4.432

5.  SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties.

Authors:  K Matsuno; T Senda; T Kobayashi; K Okamoto; K Nakata; S Mita
Journal:  Behav Brain Res       Date:  1997-02       Impact factor: 3.332

6.  TAK-147, an acetylcholinesterase inhibitor, increases choline acetyltransferase activity in cultured rat septal cholinergic neurons.

Authors:  K Kato; H Hayako; Y Ishihara; S Marui; M Iwane; M Miyamoto
Journal:  Neurosci Lett       Date:  1999-01-22       Impact factor: 3.046

7.  Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo.

Authors:  K Yamada; T Tanaka; D Han; K Senzaki; T Kameyama; T Nabeshima
Journal:  Eur J Neurosci       Date:  1999-01       Impact factor: 3.386

8.  Enhancement of acetylcholine release by SA4503, a novel sigma 1 receptor agonist, in the rat brain.

Authors:  T Kobayashi; K Matsuno; K Nakata; S Mita
Journal:  J Pharmacol Exp Ther       Date:  1996-10       Impact factor: 4.030

9.  Involvement of sigma 1 receptor in (+)-N-allylnormetazocine-stimulated hippocampal cholinergic functions in rats.

Authors:  K Matsuno; T Senda; T Kobayashi; S Mita
Journal:  Brain Res       Date:  1995-09-04       Impact factor: 3.252

10.  Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia.

Authors:  T Maurice; M Hiramatsu; J Itoh; T Kameyama; T Hasegawa; T Nabeshima
Journal:  Brain Res       Date:  1994-05-30       Impact factor: 3.252

View more
  9 in total

1.  Administration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficits.

Authors:  Ann N Hoffman; Jeffrey P Cheng; Ross D Zafonte; Anthony E Kline
Journal:  Life Sci       Date:  2008-08-31       Impact factor: 5.037

2.  The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models.

Authors:  Alvin V Terry; Jerry J Buccafusco; Elizabeth J Herman; Patrick M Callahan; Wayne D Beck; Samantha Warner; Leah Vandenhuerk; Kristy Bouchard; Gary M Schwarz; Jie Gao; James M Chapman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-24       Impact factor: 4.030

3.  The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.

Authors:  Maninder Malik; Claudia Rangel-Barajas; Nathalie Sumien; Chang Su; Meharvan Singh; Zhenglan Chen; Ren-Qi Huang; Johann Meunier; Tangui Maurice; Robert H Mach; Robert R Luedtke
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

4.  Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease.

Authors:  Valentine Lahmy; Johann Meunier; Susanna Malmström; Gaelle Naert; Laurent Givalois; Seung Hyun Kim; Vanessa Villard; Alexandre Vamvakides; Tangui Maurice
Journal:  Neuropsychopharmacology       Date:  2013-03-14       Impact factor: 7.853

Review 5.  The pharmacology of sigma-1 receptors.

Authors:  Tangui Maurice; Tsung-Ping Su
Journal:  Pharmacol Ther       Date:  2009-07-18       Impact factor: 12.310

Review 6.  Multi-Target Directed Ligands (MTDLs) Binding the σ1 Receptor as Promising Therapeutics: State of the Art and Perspectives.

Authors:  Francesca Serena Abatematteo; Mauro Niso; Marialessandra Contino; Marcello Leopoldo; Carmen Abate
Journal:  Int J Mol Sci       Date:  2021-06-14       Impact factor: 5.923

7.  Mitochondrial protection by the mixed muscarinic/σ1 ligand ANAVEX2-73, a tetrahydrofuran derivative, in Aβ25-35 peptide-injected mice, a nontransgenic Alzheimer's disease model.

Authors:  Valentine Lahmy; Romain Long; Didier Morin; Vanessa Villard; Tangui Maurice
Journal:  Front Cell Neurosci       Date:  2015-01-20       Impact factor: 5.505

Review 8.  Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders.

Authors:  Kinga Sałaciak; Karolina Pytka
Journal:  Neurosci Biobehav Rev       Date:  2021-11-01       Impact factor: 8.989

9.  Sigma-1 Receptor Activation Induces Autophagy and Increases Proteostasis Capacity In Vitro and In Vivo.

Authors:  Maximilian G Christ; Heike Huesmann; Heike Nagel; Andreas Kern; Christian Behl
Journal:  Cells       Date:  2019-03-02       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.